Search filters

List of works by Jean-Luc Harousseau

Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial

scientific article published on 23 November 2010

Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials

scientific article published on 13 October 2009

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study

scientific article published on 18 August 2008

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).

scientific article published on 2 November 2009

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

scientific article published in June 2005

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

scientific article published on 19 July 2010

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

scientific article published on 7 September 2010

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

scientific article published on 17 August 2011

Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma

scientific article

Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience

scientific article published on 24 June 2013

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-r

scientific article

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

scientific article

Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma

scientific article published on 03 December 2015

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

scientific article published on 03 February 2011

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

scientific article published on 03 February 2011

Current multiple myeloma treatment strategies with novel agents: a European perspective

scientific article published on 19 January 2010

Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone

article

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma

scientific article

Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography

scientific article published on 11 February 2008

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

scientific article published on 09 August 2007

Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.

scientific article published on January 2011

Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease

scientific article

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

scientific article published on 5 January 2007

High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma

scientific article published on 12 July 2010

Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma

scientific article published in September 2009

Individualizing treatment of patients with myeloma in the era of novel agents.

scientific article published on 21 April 2008

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

scientific article published on August 2016

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

scientific article published on 01 May 2012

Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma

scientific article published on 06 September 2008

Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study

scientific article published on 19 August 2010

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

scientific article

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

scientific article published on April 2017

Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome

article

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

scientific article published on 27 July 2006

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

scientific article published on 24 September 2018

Monoclonal antibodies in the treatment of multiple myeloma ⬇️

scientific article published on July 21, 2011

Monoclonal gammopathy of undetermined significance: a consensus statement

scientific article

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective

scientific article published on 26 March 2011

Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma

scientific article

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group

scientific article

Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group.

scientific article published on 29 April 2010

Prognostic significance of copy-number alterations in multiple myeloma

scientific article

Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy

scientific article published on 01 September 2002

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

scientific article published on 18 October 2010

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

scientific article

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma

scientific article

Stem-cell transplantation in multiple myeloma

scientific article

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

scientific article published on 13 July 2010

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R

scientific article

Thalidomide for treatment of multiple myeloma: 10 years later

scientific article published on February 2008

Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).

scientific article published in January 2002

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

scientific article

Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?

scientific article published on 20 October 2010

VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis

scientific article published on 24 June 2004

Paulina is supported by:

About Paulina

Help